| abstract |
Compounds of formula (I) are described, pharmaceutical compositions of the compounds and their uses as NOS inhibitors, wherein; n and m in the bridging rings are independently 1, 2 or 3, and a carbon in one of the bridging rings may be substituted by a heteroatom selected from O, S and N, with the proviso that a bridghead carbon can only be substituted by a nitrogen, R1 and R2 are independently selected from C1-6alkyl, which may be linear, branched or cyclic or contain both linear and cyclic branched and cyclic moieties, wherein each or R1 and R2 may be optionally substituted, or R1 and R2 form, together with the nitrogen to which they are attached, a piperazine, azetidine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members. The piperazine, azetidine, piperidine or pyrrolidine rings may be optionally substituted |